CCO Independent Conference Coverage: Clinical Impact of New Data From EASL 2021

June 23-26, 2021; Virtual
In this downloadable slideset, CCO’s expert faculty members summarize key viral hepatitis studies from this important conference, including new data on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure.
Tarik Asselah, MD, PhD
Robert G. Gish, MD
Nancy Reau, MD
Stefan Zeuzem, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 754 KB
Released: July 15, 2021

Acknowledgements

Educational grant provided by:
AbbVie
Antios Therapeutics
Gilead Sciences, Inc.

Related Content

Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)

Robert G. Gish, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Commentary from Nancy Reau on HDV and HBV

Nancy Reau, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Tarik Asselah: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Tarik Asselah, MD, PhD Released: July 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue